Andrew James King - 31 Jan 2022 Form 4 Insider Report for CHINOOK THERAPEUTICS, INC. (KDNY)

Role
Chief Scientific Officer
Signature
/s/ Kirk Schumacher, Attorney-in-Fact
Issuer symbol
KDNY
Transactions as of
31 Jan 2022
Transactions value $
$0
Form type
4
Filing time
02 Feb 2022, 16:22:36 UTC
Previous filing
12 Nov 2021
Next filing
14 Feb 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KDNY Stock Option (right to buy) Award $0 +100K $0.00 100K 31 Jan 2022 Common Stock 100K $12.90 Direct F1
transaction KDNY Restricted Stock (RSU)(Common Stock) Award $0 +25K $0.00 25K 31 Jan 2022 Common Stock 25K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 25% of the total shares on January 31, 2023, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F2 Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.
F3 The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on January 31, 2023, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date.